<DOC>
	<DOCNO>NCT01404325</DOCNO>
	<brief_summary>This trial evaluate efficacy Everolimus combination centre specific standard immunosuppressive regimen versus standard immunosuppressive regimen concern kidney function lung transplant recipient .</brief_summary>
	<brief_title>Efficacy Everolimus Combination With Specific Standard Immunosuppressive Regimen Lung Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<criteria>Inclusion criterion : Adult recipient de novo cadaveric lung transplant Exclusion criterion : Patients thrombocytopenia ( platelet &lt; 100,000/mm³ ) , absolute neutrophil count &lt; 1,500/mm³ leucopenia ( leucocytes &lt; 3000/mm³ ) , anemia Hb &lt; 8g/dl time screen Patients uncontrolled hypercholesterolemia ( &gt; 330mg/dL ; &gt; 9mmol/L ) hypertriglyceridemia ( &gt; 300 mg/dL ; &gt; 8.5 mmol/L ) time screen Patients history malignancy organ system , treat untreated , last five year , whether evidence local recurrence metastasis , except squamous basal cell carcinoma skin Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Lung transplantation</keyword>
	<keyword>everolimus</keyword>
	<keyword>kidney function</keyword>
</DOC>